Galvez: EUA For Sputnik V COVID-19 Vaccine May Come Out Within 1 To 2 Weeks

The EUA for Sputnik V COVID-19 vaccine may come out within 1 to 2 weeks, according to Galvez.

Vaccine czar Secretary Carlito Galvez Jr. on Sunday said that the emergency use authorization (EUA) for Sputnik V COVID-19 vaccine in the Philippines may come out in one to two weeks.

According to Galvez, the EUA application of Russia’s Gamaleya Research Institute was currently on its “advance stage.”

Galvez Sputnik V

In a press conference at the sidelines of the COVID-19 vaccine rollout at the QualiMed Hospital in Sta. Rosa, Laguna, Galvez said that they’re the ones facilitating the dialogue between the Food and Drug Administration (FDA), Russia’s Gamaleya Research Institute, and the Russian Direct Investment Fund.

Galvez also said that based on their assessment, the emergency use authorization (EUA) of Gamaleya for the Sputnik V COVID-19 vaccine may come out in a week or two.

Kami mismo ang nagfafacilitate ng dialogue between FDA (Food and Drug Administration) and ‘yung Gamaleya at tsaka ‘yung Russian Direct Investment Fund. So ang nakita naming assessment namin, within one week or two weeks siguro baka lumabas na ‘yung sa Gamaleya na Sputnik V,” Galvez said.

READ ALSO: FDA Appeals To Russian Embassy To Help In Expediting Gamaleya Research Institute’s EUA Application In PH

The Food and Drug Administration announced the EUA application for Gamaleya’s Sputnik V COVID-19 vaccine last January.

In November 2020, Russia said that its Sputnik V COVID-19 vaccine was 92% effective at protecting people from COVID-19 according to interim trial results.

Meanwhile, Galvez said that the Philippine government had also advised other vaccine manufacturers of COVID-19 vaccines based in the United States such as Johnson & Johnson, Novavax, and Moderna to apply for an EUA in the country.

At present, only Pfizer-BioNTech, AstraZeneca-Oxford, and Sinovac Biotech had approved emergency use authorizations in the Philippines.

The EUA applications currently pending before the local Food and Drug Administration were from Bharat Biotech, Sinopharm, and Gamaleya Institute.

For more news and updates, you may feel free to visit this site more often. You may also visit via our official Facebook page and YouTube channel.

Leave a Comment